Get access

CD133 expression is correlated with chemoresistance and early recurrence of gastric cancer

Authors

  • Han Hong Lee MD,

    1. Division of Gastrointestinal Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea
    2. Department of Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea
    Search for more papers by this author
  • Kyung Jin Seo MD,

    1. Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul, Korea
    Search for more papers by this author
  • Chang Hyeok An MD,

    1. Department of Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea
    Search for more papers by this author
  • Jeong Soo Kim MD,

    1. Department of Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea
    Search for more papers by this author
  • Hae Myung Jeon MD

    Corresponding author
    1. Division of Gastrointestinal Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea
    2. Department of Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea
    • Department of Surgery, Uijeongbu St. Mary's Hospital College of Medicine, The Catholic University of Korea 65-1 Gumo-Dong, Uijeongbu-City, Gyenggi-Do, 480-717, Korea; Fax: +82-31-847-2717.===

    Search for more papers by this author

Abstract

Background

CD133 has been suggested to be a cancer stem cell (CSC) marker in various types of cancers. The present study assessed the relationship between CD133 expression and clinicopathological features of gastric cancer. In addition, the prognostic value of CD133 for gastric cancer was evaluated.

Methods

In total, 100 advanced gastric cancer patients who received curative gastrectomy and adjuvant chemotherapy were included. CD133 expression was determined by immunohistochemistry and clinicopathological results, including survival, were analyzed.

Results

CD133 was expressed in 23% of advanced gastric cancer patients (23/100). CD133 expression was significantly associated with serosal exposure (P = 0.036), venous invasion (P = 0.047), well and moderate differentiation (P = 0.002), and intestinal-type Lauren classification (P = 0.001). CD133-positive patients had a significantly worse 5-year disease-free (28.1% vs. 65.8%, P = 0.002) and overall (47.5% vs. 74.0%, P = 0.037) survival rate than those who were CD133-negative. A multivariate analysis suggested that CD133 expression significantly affected the 5-year disease-free and overall survival.

Conclusions

CD133 may play an important role in chemoresistance and recurrence, thus representing a promising predictive marker for the prognosis of gastric cancer. J. Surg. Oncol. 2012; 106: 999–1004. © 2012 Wiley Periodicals, Inc.

Ancillary